A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers (SRD)

Targacept

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: TC-2216

Study type: Interventional

Funder types: Industry

Identifiers

NCT00583544

TC-2216-232-CLP-001

Details and patient eligibility

About

Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.

Enrollment: 72 estimated patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male subjects aged 18-40 years old (both ages included).
2. Subjects must be in good health as determined by their medical history, physical examination, psychological examination, ECG, vital signs, standard EEG and laboratory tests. A volunteer with a clinical abnormality may be included only if the Investigator or his designee considers that the abnormality will not introduce additional risk factor for the subject's health, or interfere with the study objectives.
3. Subjects with a body mass index within the range 18-29 kg/m2 and a weight within the range of 60-90 kg.
4. Non-smoker subjects (a cotinine test will be performed at screening and Day -1
5. Subjects must be able to refrain from consuming xanthine containing beverages, and must refrain from intensive physical exercise during the study conduct (until the end of study visit).
6. Subjects must have signed an informed consent form indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions.
7. Subjects must be affiliated with, or a beneficiary of, a French social security system.

Exclusion criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Any clinically relevant acute or chronic diseases which could interfere with the subjects safety during the trial, or expose them to undue risk, or which could interfere with the study objectives.
2. History or presence of gastrointestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
3. Any history of drug or other significant allergy.
4. Likely to need any treatment (including dental care) during the study period.
5. Donation of one or more units of blood within 90 days prior to the screening.
6. Use of any prescription or over-the-counter medication within 14 days prior to admission on Day-1 (not including paracetamol in the range of 1gr/day). In addition any medications with central effects are prohibited for a period equal to 5 x half-life prior to admission (Day-1), should this period be longer than 14 days.
7. Alcohol consumption > 40 g alcohol/day (1 glass (25 cl) of beer with 3° of alcohol = 7.5 g, or 1 glass (25 cl) of beer with 6° of alcohol = 15 g, or 1 glass (12.5 cl) of wine with 10° of alcohol = 12 g, or 1 glass (4cl) of aperitif with 42° of alcohol = 17 g).
8. Positive alcotest at screening and Day -1 .
9. Positive test result on hepatitis B surface antigen, hepatitis C antibody.
10. Positive test result on HIV 1 and 2 serology.
11. Excessive daily consumption of xanthines containing drinks (i.e > 500 mg/day of caffeine).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

72 participants in 2 patient groups, including a placebo group

1

Placebo Comparator group

Treatment:

Drug: TC-2216

2

Experimental group

Treatment:

Drug: TC-2216